Clinical value of endolymphatic administration of perftoran in the regulation of hemostasis system in patients having acute destructive diseases of the abdominal cavity organs

Endolymphatically administered perftoran in a dose of 15 ml, 2 times per day, administered during 10 days to patients having destructive diseases of the abdominal cavity organs was demonstrated to prevent the DVS syndrome development which resulted in decreased thrombonemia and prevented plasma factors of сoagulation deficiency ( characteristic of the second week of the disease), normal fibrinolytic activity and thrombocyte component of the hemostasis system which positively influences on the course and outcome of the disease.